Wellstat Therrpeutics has received approval from the US Food and Drug Administration (FDA) for its Vistogard (uridine triacetate) to treat adult and paediatric patients following an overdose of the chemotherapy agents 5-Fluorouracil (5-FU) or capecitabine.

It is also indicated to treat patients who exhibit early-onset and severe or life-threatening toxicity affecting cardiac or central nervous system, and early-onset and unusually severe adverse reactions within 96 hours after the end of treatment with 5-FU or capecitabine.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The drug is claimed to be the first and only antidote for emergency treatment following an overdose of the chemotherapy agents.
Wellstat’s commercialisation partner BTG will market and distribute the drug in the US.

"Wellstat has developed Vistoguard to help patients treated with 5-FU or capecitabine who develop severe or life threatening toxicity or experience an overdose."

Wellstat Therapeutics CEO Samuel Wohlstadter said: "Wellstat has developed Vistoguard to help patients treated with 5-FU or capecitabine who develop severe or life threatening toxicity or experience an overdose.

"It is the only treatment approved by the FDA for early onset severe toxicities or 5-FU overdose and now will be available to the thousands of patients impacted by this condition."

The approval was based on data from a development program in 135 patients, which demonstrated the efficacy and safety of a single course of 10g given orally every six hours for a total of 20 doses.

According to the firm, the studies showed that overall survival of patients with 5-FU toxicity receiving Vistoguard was 96% compared against 16%in historical cases employing standard supportive care measures.

Vistoguard also received orphan drug designation from the FDA as an antidote in the treatment of 5-FU poisoning and from the European Medicines Agency (EMA) as a treatment for 5-FU overdose.